On November 20, 2023, JP Morgan analyst Jessica Fye made a significant move by reinstating coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Neutral rating. This recent decision showcases JP Morgan’s current stance on Esperion Therapeutics, emphasizing their renewed interest in the company’s potential. By taking this step, Fye highlights the importance of closely monitoring Esperion Therapeutics’ progress in the evolving market landscape.
Esperion Therapeutics, Inc.
ESPR
Neutral
Updated on: 29/11/2023
Weak 
DCF: Strong Buy 
ESPR Stock Fluctuates on November 20, 2023: Analyzing Earnings Growth, Revenue Decline, and Net Profit Margin
ESP Resources, Inc. (ESPR) is a pharmaceutical company specializing in the development and commercialization of novel therapies for rare and life-threatening diseases. On November 20, 2023, ESPR stock showed fluctuations in its performance.
The previous day’s closing price of ESPR stock was $1.19, and it opened at $1.20 on November 20. Throughout the day, the stock had a range of $1.16 to $1.30. The trading volume for the day stood at 112,650 shares, significantly lower than the average volume of 3,663,677 shares over the past three months.
ESP Resources has a market capitalization of $125.7 million. The company’s earnings growth rate was 62.21% in the previous year, with a projected growth rate of 36.28% for the current year. The forecasted growth rate for the next five years is 46.80%.
However, the company’s revenue growth has declined by 3.79% in the past year. The P/E ratio for ESPR stock is not available (NM), and the price/sales ratio is 5.48.
ESP Resources operates in the Health Technology sector and falls under the Pharmaceuticals: Major industry. The company’s headquarters are located in Ann Arbor, Michigan.
Looking ahead, ESPR’s next reporting date is scheduled for February 20, 2024. Analysts forecast an earnings per share (EPS) of -$0.42 for this quarter. In the previous year, the company reported an annual revenue of $75.5 million but incurred a net loss of -$233.7 million. The negative net profit margin of -309.58% indicates that the company’s expenses exceed its revenue.
Overall, ESPR stock showed volatility on November 20, 2023, with fluctuations in its price range. While the company has demonstrated strong earnings growth, the decline in revenue and negative net profit margin are areas of concern. Investors should closely monitor the company’s financial performance and future developments to make informed investment decisions.
Esperion Therapeutics Inc (ESPR) Stock Analysis: Promising Performances and Potential Future Growth
On November 20, 2023, Esperion Therapeutics Inc (ESPR) stock showed promising performances based on the information provided by CNN Money. The stock had a last price of 1.24, and the 8 analysts offering 12-month price forecasts had a median target of 7.00, with a high estimate of 22.00 and a low estimate of 2.00. This indicates a potential increase of +466.80% from the last price.
The consensus among the 8 polled investment analysts is to buy stock in Esperion Therapeutics Inc. This rating has remained steady since September, when it was unchanged from a buy rating. This suggests that the analysts have confidence in the future performance of the company and believe it is a good investment opportunity.
In terms of financial performance, Esperion Therapeutics Inc reported an earnings per share of -$0.42 for the current quarter. While this indicates a loss, it is important to consider the context and potential future growth. The company’s sales for the current quarter were $34.7 million, which shows a solid revenue stream.
Investors should keep an eye on Esperion Therapeutics Inc as the reporting date for the current quarter is set for February 20. This will provide further insights into the company’s financial health and potential future growth.
Overall, based on the median target price and the consensus among investment analysts, Esperion Therapeutics Inc appears to be a promising investment opportunity. However, it is important for investors to conduct their own research and analysis before making any investment decisions.
Discussion about this post